



## Review

# Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP)

Elena Santagostino\*

Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Granda Foundation, Maggiore Hospital Policlinico and University of Milan, Milan, Italy

## KEYWORDS

Hemophilia B  
PROLONG-9FP  
rIX-FP  
Recombinant factor IX  
On-demand  
Prophylaxis

## ABSTRACT

Recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP; Idelvion®) is an innovative new treatment designed to extend the half-life of factor IX (FIX) and ease the burden of care for hemophilia B patients. The rIX-FP clinical development program – PROLONG-9FP – is in its advanced phases, with pivotal studies in previously treated adults, adolescents, and pediatrics now completed. Across all age groups studied, rIX-FP has demonstrated a markedly improved pharmacokinetic profile compared with plasma-derived and recombinant FIX treatments, with a 30–40% higher incremental recovery, an approximately 5-fold longer half-life, a lower clearance, and a greater area under the curve. rIX-FP has been very well tolerated with an excellent safety profile. In the pivotal studies, there have been no reports of FIX inhibitors or antidrug antibodies, and few treatment-related adverse events have been observed. Prophylactic regimens of rIX-FP administered once weekly to once every 14 days have been highly effective. When used for surgical prophylaxis, a single infusion of rIX-FP has been sufficient to maintain hemostasis, even during major orthopedic surgery. An ongoing study is now enrolling previously untreated patients and evaluating the possibility of extending the dosing interval to every 21 days. There is little doubt that rIX-FP will transform the treatment of hemophilia B.

© 2016 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

## Introduction

Recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP; Idelvion®) is an innovative new treatment that was developed to extend the half-life of factor IX (FIX) and improve the lives of people with hemophilia B. The molecule was designed with a cleavable linker between the recombinant factor IX (rFIX) and the recombinant albumin moieties, allowing the fusion protein to benefit optimally from albumin's long half-life, while preserving the function of the wild-type coagulation factor [1,2]. The clinical development program for rIX-FP – PROLONG-9FP – was initiated in 2010 and is now in its advanced phases, with pivotal phase III studies in previously treated adults, adolescents, and pediatrics completed (Figure 1). A long-term extension study is ongoing. This paper provides an update on the clinical development of rIX-FP for the treatment of patients with hemophilia B.

## Phase I study of the safety and pharmacokinetics (PK) of rIX-FP in previously treated adults and adolescents with severe hemophilia B

This first-in-human study enrolled 25 previously treated adolescents and adults (mean age 35 years; range 15–58 years) with severe hemophilia B (FIX activity  $\leq 2\%$ ) and evaluated the safety and PK of single intravenous (IV) doses of rIX-FP at 25, 50, and 75 IU/kg when administered to patients in a non-bleeding state [3]. Patients who participated in the rIX-FP 50 IU/kg cohort also received a single 50 IU/kg dose of their previous FIX treatment for PK assessments. The primary objective of the study was to assess the safety of rIX-FP based on the occurrence of adverse events (AEs), inhibitors against FIX, antibodies against rIX-FP, local tolerability, physical examinations and vital signs, urinalysis, and laboratory assessments.


The tolerability of rIX-FP was found to be excellent in this study. There were no hypersensitivity reactions and no patients developed inhibitors to FIX or antidrug antibodies [3]. Only four AEs were considered to be possibly related to rIX-FP (mild headache, feeling hot 50 minutes after the injection, mild constipation, and mild erythema at the injection site), all of which resolved on the same day without treatment.

This study was the first to demonstrate the remarkable PK profile of rIX-FP and generated considerable excitement amongst

† License approval received March 2016 in the USA

\* Corresponding author at: Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Granda Foundation, Maggiore Hospital Policlinico, Via Pace 9, 20122 Milan, Italy. Tel.: +39 02 55035273; fax: +39 02 55032072.

E-mail address: [elena.santagostino@policlinico.mi.it](mailto:elena.santagostino@policlinico.mi.it) (E. Santagostino).



**Fig. 1.** PROLONG-9FP clinical program for evaluating the recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP) in patients with severe hemophilia B. PK, pharmacokinetics; PUPs, previously untreated patients. Reproduced with permission from Schattauer GmbH: Swiss Medical Press GmbH. News from the XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Toronto, Canada. Pioneering therapeutic proteins in hemophilia care through innovative technologies. *Thromb Haemost* 2016;115:VI–X.

the hemophilia community. In the cohort of patients who received 50 IU/kg of rIX-FP and 50 IU/kg of either plasma-derived FIX (pdFIX) or rFIX (BeneFIX®), the mean half-life of rIX-FP was 92 hours, which was more than 5-fold longer than that of rFIX and more than 6-fold longer than that of pdFIX when used in the same patients. Importantly, mean FIX activity levels remained above 5% at the 2-week (36 hours) PK assessment – an unprecedented finding. Compared with the other FIX treatments assessed in this study, rFIX-FP was also associated with a substantially reduced clearance and greater area under the curve.

#### Phase I/II study of the safety, efficacy, and PK of rIX-FP in previously treated adults and adolescents with severe hemophilia B

This phase I/II, open-label study was conducted to evaluate the safety, PK, and efficacy of rIX-FP when used for weekly prophylaxis and on demand for the treatment of bleeding episodes [4]. The study enrolled 17 previously treated patients (mean age 26 years; range 13–46 years) with severe hemophilia B (FIX activity  $\leq 2\%$ ). All patients entered a 10–14-day PK evaluation period, followed by an 11-month safety and efficacy evaluation period in which patients continued using rIX-FP either on demand (at a minimum dose of 25 IU/kg) or as prophylaxis. Thirteen patients received prophylaxis with rIX-FP throughout the study (range 37–48 weeks); of these 13 patients, three patients switched from an on-demand regimen with their previous FIX treatment to rIX-FP prophylaxis, and 10 patients continued prophylaxis but switched from their previous FIX product to rFIX-FP. Four patients switched from an on-demand regimen with their previous FIX treatment to rIX-FP on demand for the duration of the study (range 15–22 weeks).

The PK profile of the 25 IU/kg dose of rIX-FP was similar to that described in the phase I study. The mean incremental recovery of rIX-FP 25 IU/kg was 1.52 IU/dL per IU/kg, and the mean half-life was 94.8 hours [4]. The mean baseline-corrected FIX activity levels were 5.6% at Day 7 and 2.9% at Day 14 [4]. rIX-FP was well tolerated during a total exposure of over 700 days. None of the patients developed inhibitors to FIX or antibodies to rIX-FP. There were no hypersensitivity reactions and no significant treatment-emergent safety issues. None of the AEs reported were considered by the investigators to be related to rIX-FP, and no one withdrew from the study because of AEs.

The efficacy of rIX-FP was excellent when used as on-demand treatment and for prophylaxis [4]. A total of 85 bleeding episodes were treated with rIX-FP and all were treated successfully with one (95.3%) or two (4.7%) doses. Almost half (46%) of the patients receiving rIX-FP prophylaxis did not experience a single bleeding episode during this 11-month study [4].

Patients receiving rIX-FP prophylaxis experienced fewer spontaneous bleeding episodes than those receiving on-demand rIX-FP. A mean annualized spontaneous bleeding rate (AsBR) of 21.74 was reported for patients receiving rIX-FP on demand – a 20% reduction compared with their historical AsBR (Figure 2a). Patients receiving rIX-FP prophylaxis had a mean AsBR of 1.26 – a 50% reduction compared with their historical AsBR (Figure 2a). Most notably, however, patients switching from on-demand treatment with a previous FIX product to rIX-FP prophylaxis experienced a 95% reduction in AsBR (Figure 2a). Similar findings were observed for the total annualized bleeding rate (Figure 2b).

The results of this study confirmed that rIX-FP had an excellent safety and tolerability profile and that, as a result of its favorable PK profile, weekly prophylaxis was feasible and effective.

#### Phase II/III study of the efficacy and safety of rIX-FP in previously treated adults and adolescents with severe hemophilia B

The results of the pivotal phase II/III study of rIX-FP in previously treated adolescents and adults with severe hemophilia B (FIX activity  $\leq 2\%$ ) [5] have recently been presented [6,7]. The study was designed to evaluate the long-term efficacy and safety of rIX-FP when used on demand and in prophylactic regimens of every 7, 10, and 14 days (Figure 3). All patients initially participated in a 14-day PK evaluation period and received a single dose of rIX-FP 50 IU/kg. Patients were subsequently allocated to one of two treatment groups: Group 1 received rIX-FP prophylaxis every 7 days for 6 months, then, where appropriate, the dosing interval could be extended to every 10 or 14 days. Patients in Group 2 received rIX-FP on demand for 6 months, and then switched to prophylaxis every 7 days. The primary efficacy endpoint was the change in AsBR between on-demand and once-weekly prophylaxis with rIX-FP, as assessed in study Group 2 [5].

A total of 63 patients took part in the study at centers in Europe, Japan, Israel, and the USA [7]. Nineteen patients switched from on-demand treatment with rIX-FP to weekly prophylaxis [7]. The median AsBR during rIX-FP on-demand treatment in this group of individuals was 15.43, which reduced to a median of 0.00 after switching to weekly rIX-FP prophylaxis – a highly statistically significant reduction of 100% ( $p < 0.0001$ ). Twenty-one patients extended their treatment interval to once every 14 days. The median AsBR amongst all prophylaxis patients on 7-, 10- and 14-day regimens ( $n=40$ ) was 0.00; rIX-FP administered every 14 days was as effective as once-weekly prophylaxis. Moreover, patients receiving rIX-FP prophylaxis every 14 days were able to reduce the consumption of their previous FIX product by 50% [7].

rIX-FP was also effective at treating bleeds in this study [7]. Overall, 98.6% of bleeds were successfully treated with  $\leq 2$  injections

Download English Version:

<https://daneshyari.com/en/article/3026909>

Download Persian Version:

<https://daneshyari.com/article/3026909>

[Daneshyari.com](https://daneshyari.com)